Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2020 Filed Feb 24, 2020 22:10 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 16,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003291 · doc4.xml · derivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,474 Underlying: Common Stock · 16,824 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:10 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 7,470 | $42.62 | $318,371.40 |
DisclosureSEC source: 0001225208-20-003291 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,183,516 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:10 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 16,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003291 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,190,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · derivative · entry 7 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,178 Underlying: Common Stock · 2,726 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 1,237 | $42.62 | $52,720.94 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,028 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionCommon Stock | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003289 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC |
Eddy Jodi EuerleSVP and CIO
|
Exercise / conversionDeferred Stock Units · Derivative | 934 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003286 · doc4.xml · derivative · entry 7 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,804 Underlying: Common Stock · 934 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC |
Eddy Jodi EuerleSVP and CIO
|
Tax withholdingCommon Stock | 320 | $42.62 | $13,638.40 |
DisclosureSEC source: 0001225208-20-003286 · doc4.xml · nonDerivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,516 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC |
Eddy Jodi EuerleSVP and CIO
|
Exercise / conversionCommon Stock | 934 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003286 · doc4.xml · nonDerivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 1,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003284 · doc4.xml · derivative · entry 7 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,674 Underlying: Common Stock · 1,557 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 701 | $42.62 | $29,876.62 |
DisclosureSEC source: 0001225208-20-003284 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,677 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 1,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003284 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 1,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003283 · doc4.xml · derivative · entry 8 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,141 Underlying: Common Stock · 1,713 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Tax withholdingCommon Stock | 521 | $42.62 | $22,205.02 |
DisclosureSEC source: 0001225208-20-003283 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,174 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 1,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003283 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionDeferred Stock Units · Derivative | 3,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003282 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,983 Underlying: Common Stock · 3,660 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 1,660 | $42.62 | $70,749.20 |
DisclosureSEC source: 0001225208-20-003282 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,697 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 3,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003282 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionDeferred Stock Units · Derivative | 2,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · derivative · entry 7 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,880 Underlying: Common Stock · 2,959 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 1,350 | $42.62 | $57,537.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,477 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 2,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:32 UTC |
Pierce David AEVP Pres MedSurg
|
SaleCommon Stock | 1,511 | $42.31 | $63,930.41 |
DisclosureSEC source: 0001225208-20-002842 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,540 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:28 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 1,757 | $42.31 | $74,338.67 |
DisclosureSEC source: 0001225208-20-002830 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,868 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:09 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GiftCommon Stock | 10,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003287 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,102 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
GrantStock Option (Right to Buy) · Derivative | 29,867 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002846 · doc4.xml · derivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,867 Underlying: Common Stock · 29,867 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
GrantDeferred Stock Units · Derivative | 8,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002846 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,005 Underlying: Common Stock · 8,005 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
GrantStock Option (Right to Buy) · Derivative | 25,442 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002843 · doc4.xml · derivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,442 Underlying: Common Stock · 25,442 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
GrantDeferred Stock Units · Derivative | 6,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002843 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819 Underlying: Common Stock · 6,819 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantStock Option (Right to Buy) · Derivative | 17,699 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002845 · doc4.xml · derivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,699 Underlying: Common Stock · 17,699 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantDeferred Stock Units · Derivative | 4,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002845 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,743 Underlying: Common Stock · 4,743 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002844 · doc4.xml · derivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Stock · 16,592 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:33 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
GrantDeferred Stock Units · Derivative | 4,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002844 · doc4.xml · derivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,447 Underlying: Common Stock · 4,447 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantStock Option (Right to Buy) · Derivative | 26,548 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002841 · doc4.xml · derivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,548 Underlying: Common Stock · 26,548 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantDeferred Stock Units · Derivative | 7,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002841 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,115 Underlying: Common Stock · 7,115 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC |
Pierce David AEVP Pres MedSurg
|
GrantStock Option (Right to Buy) · Derivative | 39,823 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002842 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,823 Underlying: Common Stock · 39,823 shares Expires 2030-02-18 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:32 UTC |
Pierce David AEVP Pres MedSurg
|
GrantDeferred Stock Units · Derivative | 10,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002842 · doc4.xml · derivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,673 Underlying: Common Stock · 10,673 shares Expires 2024-02-18 F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Monson JonathanVP, Corp Controller and CAO
|
GrantStock Option (Right to Buy) · Derivative | 10,346 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002840 · doc4.xml · derivative · entry 2 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,346 Underlying: Common Stock · 10,346 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Monson JonathanVP, Corp Controller and CAO
|
GrantDeferred Stock Units · Derivative | 2,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002840 · doc4.xml · derivative · entry 1 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,549 Underlying: Common Stock · 2,549 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 42,035 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002839 · doc4.xml · derivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,035 Underlying: Common Stock · 42,035 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GrantDeferred Stock Units · Derivative | 11,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002839 · doc4.xml · derivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,266 Underlying: Common Stock · 11,266 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantStock Option (Right to Buy) · Derivative | 15,486 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002838 · doc4.xml · derivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,486 Underlying: Common Stock · 15,486 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantDeferred Stock Units · Derivative | 4,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002838 · doc4.xml · derivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 Underlying: Common Stock · 4,150 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 243,362 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002837 · doc4.xml · derivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,362 Underlying: Common Stock · 243,362 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:31 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantDeferred Stock Units · Derivative | 65,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002837 · doc4.xml · derivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,227 Underlying: Common Stock · 65,227 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Mackey Edward FEVP, Operations
|
GrantStock Option (Right to Buy) · Derivative | 33,185 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002836 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,185 Underlying: Common Stock · 33,185 shares Expires 2030-02-18 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Mackey Edward FEVP, Operations
|
GrantDeferred Stock Units · Derivative | 8,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002836 · doc4.xml · derivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,894 Underlying: Common Stock · 8,894 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Mackey Edward FEVP, Operations
|
GrantDeferred Stock Units · Derivative | 23,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002836 · doc4.xml · derivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,719 Underlying: Common Stock · 23,719 shares Expires 2022-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in one installment on February 18, 2022, the second anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in one installment on February 18, 2022, the second anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Eddy Jodi EuerleSVP and CIO
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002834 · doc4.xml · derivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Stock · 16,592 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Eddy Jodi EuerleSVP and CIO
|
GrantDeferred Stock Units · Derivative | 4,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002834 · doc4.xml · derivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,447 Underlying: Common Stock · 4,447 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GrantStock Option (Right to Buy) · Derivative | 55,309 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002835 · doc4.xml · derivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,309 Underlying: Common Stock · 55,309 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.